

Robert S Kerbel

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5274582/robert-s-kerbel-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164
papers

23,268
citations

66
h-index

152
g-index

173
ext. papers

25,206
ext. citations

12.1
avg, IF

7.39
L-index

#	Paper	IF	Citations
164	Angiogenesis as a therapeutic target. <i>Nature</i> , 2005 , 438, 967-74	50.4	2127
163	Tumor angiogenesis. <i>New England Journal of Medicine</i> , 2008 , 358, 2039-49	59.2	1788
162	Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. <i>Cancer Cell</i> , 2009 , 15, 232-9	24.3	1455
161	Clinical translation of angiogenesis inhibitors. <i>Nature Reviews Cancer</i> , 2002 , 2, 727-39	31.3	1299
160	The anti-angiogenic basis of metronomic chemotherapy. <i>Nature Reviews Cancer</i> , 2004 , 4, 423-36	31.3	1156
159	Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. <i>Journal of Clinical Investigation</i> , 2000 , 105, R15-24	15.9	884
158	Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 210-21	19.4	534
157	Antiangiogenic therapy in oncology: current status and future directions. <i>Lancet, The</i> , 2016 , 388, 518-29	40	507
156	Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. <i>Science</i> , 2006 , 313, 1785-7	33.3	505
155	The multifaceted circulating endothelial cell in cancer: towards marker and target identification. <i>Nature Reviews Cancer</i> , 2006 , 6, 835-45	31.3	505
154	Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. <i>Science</i> , 2006 , 312, 1171-5	33.3	403
153	Effect of p53 status on tumor response to antiangiogenic therapy. <i>Science</i> , 2002 , 295, 1526-8	33.3	382
152	Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. <i>BioEssays</i> , 1991 , 13, 31-6	4.1	378
151	Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. <i>Cancer Cell</i> , 2008 , 14, 263-73	24.3	375
150	A role for survivin in chemoresistance of endothelial cells mediated by VEGF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 4349-54	11.5	375
149	Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. <i>Cancer Research</i> , 2003 , 63, 4342-6	10.1	333
148	Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 17069-74	11.5	331

147	Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. <i>Cancer Research</i> , 2007 , 67, 3560-4	10.1	330
146	Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. <i>Cancer Cell</i> , 2005 , 7, 101-11	24.3	315
145	Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. <i>Cancer Research</i> , 2002 , 62, 6938-43	10.1	290
144	Mouse models of advanced spontaneous metastasis for experimental therapeutics. <i>Nature Reviews Cancer</i> , 2011 , 11, 135-41	31.3	289
143	Consensus guidelines for the use and interpretation of angiogenesis assays. <i>Angiogenesis</i> , 2018 , 21, 425-53	53.8	285
142	Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. <i>Nature Medicine</i> , 1996 , 2, 1204-10	50.5	275
141	Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. <i>Cancer Research</i> , 2009 , 69, 7243-51	10.1	274
140	Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 310-324	19.4	234
139	Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. <i>Clinical Cancer Research</i> , 2009 , 15, 5020-5	12.9	231
138	Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. <i>Blood</i> , 2005 , 106, 3058-61	2.2	224
137	Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. <i>Blood</i> , 2006 , 108, 452-9	2.2	221
136	Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. <i>Cancer Research</i> , 2002 , 62, 2731-5	10.1	211
135	Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. <i>Cancer Research</i> , 2006 , 66, 3386-91	10.1	197
134	Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. <i>Cancer and Metastasis Reviews</i> , 2001 , 20, 79-86	9.6	191
133	Drug rechallenge and treatment beyond progression--implications for drug resistance. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 571-87	19.4	174
132	Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. <i>Cancer Biology and Therapy</i> , 2003 , 2, S134-9	4.6	173
131	Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. <i>Oncogene</i> , 2000 , 19, 4611-20	9.2	170
130	Vessel co-option in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 469-493	19.4	158

129	Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. <i>Cancer Research</i> , 2004 , 64, 6616-25	10.1	150
128	Forty-year journey of angiogenesis translational research. <i>Science Translational Medicine</i> , 2011 , 3, 114rv3	17.5	144
127	Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. <i>Cancer Research</i> , 2006 , 66, 3639-48	10.1	140
126	Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. <i>Cancer</i> , 2003 , 98, 1643-8	6.4	139
125	Focused ultrasound delivers targeted immune cells to metastatic brain tumors. <i>Cancer Research</i> , 2013 , 73, 1892-9	10.1	137
124	Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. <i>International Journal of Cancer</i> , 1997 , 74, 464-9	7.5	137
123	Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. <i>Clinical Cancer Research</i> , 2006 , 12, 904-16	12.9	127
122	A Naturally Occurring Soluble Form of Vascular Endothelial Growth Factor Receptor 2 Detected in Mouse and Human Plasma. <i>Molecular Cancer Research</i> , 2004 , 2, 315-326	6.6	125
121	Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived But They Can Be Improved. <i>Cancer Biology and Therapy</i> , 2003 , 2, 133-138	4.6	121
120	Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. <i>Cancer Research</i> , 2005 , 65, 7045-51	10.1	121
119	Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. <i>Journal of Pathology</i> , 2017 , 241, 362-374	9.4	119
118	A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. <i>Cancer Research</i> , 2004 , 64, 3994-4000	10.1	119
117	Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 659-673	19.4	112
116	Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. <i>Cancer Research</i> , 2008 , 68, 4500-5	10.1	109
115	Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	105
114	A role for the TGFbeta-Par6 polarity pathway in breast cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 14028-33	11.5	103
113	Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. <i>Cancer Research</i> , 2007 , 67, 7055-8	10.1	103
112	High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. <i>Clinical Cancer Research</i> , 2006 , 12, 5190-8	12.9	93

111	Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 996-1006	6.1	92
110	Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. <i>Gut</i> , 2013 , 62, 259-71	19.2	89
109	Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. <i>Cancer Treatment Reviews</i> , 2012 , 38, 673-88	14.4	85
108	Microultrasound Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 in a Mouse Model of Tumor Angiogenesis. <i>Molecular Imaging</i> , 2007 , 6, 7290.2007.00024	3.7	85
107	Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. <i>International Journal of Cancer</i> , 1999 , 81, 118-24	7.5	82
106	Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. <i>Cancer Research</i> , 2009 , 69, 7524-8	10.1	78
105	Molecular and cellular biomarkers for angiogenesis in clinical oncology. <i>Drug Discovery Today</i> , 2007 , 12, 806-12	8.8	78
104	Non-angiogenic tumours and their influence on cancer biology. <i>Nature Reviews Cancer</i> , 2018 , 18, 323-336	1.3	77
103	A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. <i>Cancer Research</i> , 2013 , 73, 2743-8	10.1	75
102	Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival. <i>Neuro-Oncology</i> , 2016 , 18, 974-81	1	73
101	Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2872-81	6.1	72
100	In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. <i>Cancer Research</i> , 2005 , 65, 5365-73	10.1	69
99	Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. <i>Oncogene</i> , 1999 , 18, 1023-32	9.2	68
98	Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. <i>Clinical Cancer Research</i> , 2011 , 17, 5656-67	12.9	64
97	Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy. <i>Trends in Cancer</i> , 2017 , 3, 529-541	1.5	63
96	Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. <i>Clinical Cancer Research</i> , 2006 , 12, 4331-8	12.9	63
95	Extensive multi-organ metastasis following orthotopic onplantation of histologically-intact human bladder carcinoma tissue in nude mice. <i>International Journal of Cancer</i> , 1991 , 49, 938-9	7.5	61
94	Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 808-18	12.9	57

93	Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. <i>Neoplasia</i> , 2010 , 12, 928-40	6.4	57
92	Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. <i>Cancer Cell</i> , 2005 , 8, 269-71	24.3	57
91	PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. <i>Clinical Cancer Research</i> , 2015 , 21, 2138-47	12.9	56
90	Reappraising antiangiogenic therapy for breast cancer. <i>Breast</i> , 2011 , 20 Suppl 3, S56-60	3.6	54
89	Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. <i>Angiogenesis</i> , 2012 , 15, 275-86	10.6	53
88	Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. <i>Neoplasia</i> , 2011 , 13, 40-8	6.4	51
87	Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2015 , 75, 2510-9	10.1	50
86	G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. <i>Blood</i> , 2011 , 118, 3426-35	2.2	50
85	Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1816-32	2.2	50
84	Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. <i>Journal of Cellular Physiology</i> , 1994 , 159, 245-55	7	50
83	Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. <i>MABs</i> , 2010 , 2, 199-208	6.6	47
82	Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. <i>Oncogene</i> , 2000 , 19, 395-402	9.2	46
81	What is the optimal rodent model for anti-tumor drug testing?. <i>Cancer and Metastasis Reviews</i> , 1998 , 17, 301-4	9.6	44
80	The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease. <i>Cancer Letters</i> , 2017 , 400, 293-304	9.9	43
79	Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016 , 76, 4493-503	10.1	43
78	Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. <i>Neoplasia</i> , 2010 , 12, 264-74	6.4	43
77	Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. <i>Science Translational Medicine</i> , 2015 , 7, 282ra50	17.5	40
76	A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment. <i>Cancer Journal (Sudbury, Mass)</i> , 2015 , 21, 274-83	2.2	40

75	Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. <i>Cancer Research and Treatment</i> , 2007 , 39, 150-9	5.2	40
74	Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 2280-9	6.1	40
73	On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. <i>Cancer and Metastasis Reviews</i> , 2007 , 26, 737-47	9.6	39
72	Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. <i>Clinical Cancer Research</i> , 2009 , 15, 6358-66	12.9	37
71	Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy. <i>Cancer Cell</i> , 2009 , 15, 3-5	24.3	37
70	Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy. <i>Cancer Research</i> , 2016 , 76, 5983-5993	10.1	36
69	Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers. <i>Cancer Research</i> , 2016 , 76, 6988-7000	10.1	36
68	Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastasis. <i>Breast</i> , 2013 , 22 Suppl 2, S57-65	3.6	35
67	Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 680-9	6.1	34
66	Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. <i>Oncotarget</i> , 2015 , 6, 42396-410	3.3	33
65	Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. <i>EMBO Molecular Medicine</i> , 2014 , 6, 1561-76	12	31
64	Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1484-94	6.1	31
63	Differential post-surgical metastasis and survival in SCID, NOD-SCID and NOD-SCID-IL-2R(hull) mice with parental and subline variants of human breast cancer: implications for host defense mechanisms regulating metastasis. <i>PLoS ONE</i> , 2013 , 8, e71270	3.7	31
62	Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1465-73	5.6	30
61	Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2012 , 17, 229-39	2.4	30
60	Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. <i>Clinical Cancer Research</i> , 2009 , 15, 4867-74	12.9	30
59	Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. <i>Breast</i> , 2009 , 18 Suppl 3, S41-7	3.6	30
58	Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. <i>Translational Oncology</i> , 2013 , 6, 511-9	4.9	29

57	Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 3452-9	6.1	29
56	Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. <i>Neoplasia</i> , 2011 , 13, 187-97	6.4	28
55	Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer. <i>Recent Results in Cancer Research</i> , 2010 , 180, 165-83	1.5	26
54	The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor. <i>Angiogenesis</i> , 1998 , 2, 203-17	10.6	25
53	Antiangiogenic drugs and current strategies for the treatment of lung cancer. <i>Seminars in Oncology</i> , 2004 , 31, 54-60	5.5	25
52	Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. <i>Ecancermedicalscience</i> , 2014 , 8, 463	2.7	25
51	Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis. <i>Angiogenesis</i> , 2014 , 17, 641-59	10.6	24
50	Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy. <i>Clinical Cancer Research</i> , 2015 , 21, 5488-98	12.9	23
49	Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2. <i>EMBO Molecular Medicine</i> , 2015 , 7, 770-87	12	23
48	Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 313-4	19.4	22
47	Five years of clinical experience with metronomic chemotherapy: achievements and perspectives. <i>Oncology Research and Treatment</i> , 2007 , 30, 606-8	2.8	20
46	Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note. <i>PLoS ONE</i> , 2016 , 11, e0158034	3.7	20
45	Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 16	12.8	20
44	Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases. <i>Scientific Reports</i> , 2018 , 8, 9013	4.9	20
43	Peering into the aftermath: The inhospitable host?. <i>Nature Medicine</i> , 2010 , 16, 1084-5	50.5	19
42	Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. <i>Oncogene</i> , 2020 , 39, 187-203	9.2	19
41	Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. <i>Chinese Journal of Cancer</i> , 2016 , 35, 97		17
40	Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment. <i>Angiogenesis</i> , 2014 , 17, 129-46	10.6	17

39	Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. <i>British Journal of Cancer</i> , 2019 , 120, 196-206	8.7	17
38	Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. <i>Angiogenesis</i> , 2014 , 17, 661-73	10.6	16
37	Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 869-882	6.1	14
36	Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis. <i>Leukemia Research</i> , 2014 , 38, 756-63	2.7	14
35	Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2015 , 20, 1351-2	5.7	13
34	Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer. <i>Scientific Reports</i> , 2016 , 6, 36694	4.9	13
33	Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines. <i>International Journal of Cancer</i> , 1991 , 48, 557-61	7.5	10
32	Metronomic chemotherapy offsets HIF α induction upon maximum-tolerated dose in metastatic cancers. <i>EMBO Molecular Medicine</i> , 2020 , 12, e11416	12	9
31	Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 29	7.8	9
30	Therapy-activated stromal cells can dictate tumor fate. <i>Journal of Experimental Medicine</i> , 2016 , 213, 2831-2839	12.8	9
29	A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature. <i>Cancer Cell</i> , 2017 , 31, 469-471	24.3	7
28	Differential expression patterns of S100a2, S100a4 and S100a6 during progression of human malignant melanoma 1997 , 74, 464		6
27	Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1602-1612	6.1	5
26	Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor. <i>European Journal of Pharmacology</i> , 2003 , 477, 17-21	5.3	5
25	Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice. <i>PLoS ONE</i> , 2018 , 13, e0196892	3.7	5
24	Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. <i>PLoS ONE</i> , 2019 , 14, e0222580	3.7	4
23	Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity. <i>Angiogenesis</i> , 2019 , 22, 535-546	10.6	3
22	Commentaries on tumor angiogenesis: an introduction. <i>Cancer and Metastasis Reviews</i> , 1996 , 15, 145-147.	10.6	3

21	A new Tie1 targeted antibody blocks tumor cell extravasation and metastasis. <i>EMBO Molecular Medicine</i> , 2020 , 12, e12355	12	3
20	Some guidelines for building a successful career in cancer research. <i>Cancer Biology and Therapy</i> , 2003 , 2, 111-4	4.6	2
19	Development and Evolution of the Concept of Metronomic Chemotherapy: A Personal Perspective 2014 , 3-21		2
18	Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. <i>EMBO Molecular Medicine</i> , 2021 , 13, e08253	12	2
17	Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models. <i>Angiogenesis</i> , 2018 , 21, 793-804	10.6	2
16	Metronomic Chemotherapy for Treatment of Metastatic Disease: From Preclinical Research to Clinical Trials 573-586		1
15	Tumor Angiogenesis and the Cancer Stem Cell Model 2008 , 249-258		1
14	Adjuvant metronomic chemotherapy for locoregionally advanced nasopharyngeal carcinoma. <i>Lancet, The</i> , 2021 , 398, 278-279	40	1
13	Combining Antiangiogenic Drugs with Vascular Disrupting Agents Rationale and Mechanisms of Action 2010 , 117-134		1
12	Tumors resurrect an embryonic vascular program to escape immunity.. <i>Science Immunology</i> , 2022 , 7, eabm8388	16	0
11	Mouse Models of Advanced Spontaneous Metastasis for Experimental Therapeutics. <i>Methods and Principles in Medicinal Chemistry</i> , 2016 , 109-127	0.4	
10	Development of Orthotopic and Spontaneous Metastatic Human Tumor Xenograft Models for Experimental Therapeutics. <i>Molecular and Translational Medicine</i> , 2017 , 161-182	0.4	
9	Lessons from the first ecancer symposium on angiogenesis in gastric cancer. <i>Ecancermedicalscience</i> , 2015 , 9, 553	2.7	
8	Reply to [Limitations of combination anti-angiogenesis and chemotherapy] <i>Nature Reviews Cancer</i> , 2002 , 2, 804-804	31.3	
7	Angiogenesis Inhibitors as Enabling Agents for the Chemotherapeutic Treatment of Metastatic Disease 2008 , 63-80		
6	Taxanes Induce a Rapid Mobilization of Different Populations of Circulating Endothelial Progenitors by SDF-1 Modulation in Cancer Patients.. <i>Blood</i> , 2008 , 112, 1885-1885	2.2	
5	Impact of Endothelial Progenitor Cells on Tumor Angiogenesis and Outcome of Antiangiogenic Therapy: New Perspectives on an Ongoing Controversy 2010 , 257-273		
4	Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion 2019 , 14, e0222580		

- 3 Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion **2019**, 14, e0222580
- 2 Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion **2019**, 14, e0222580
- 1 Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion **2019**, 14, e0222580